Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 17/20 | 0.60 |
| ▸ | JAK2 | O60674 | 5/20 | 0.57 |
| ▸ | JAK1 | P23458 | 1/20 | 0.57 |
| ▸ | TYK2 | P29597 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 6/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL323969 | 0.92 | JAK3 (0.66) | JAK3JAK2JAK1TYK2LCK | |
| SCHEMBL10277773 | 0.84 | JAK3 (0.66) | JAK3JAK2JAK1TYK2LCK | |
| SCHEMBL322963 | 0.81 | JAK3 (0.89) | JAK3JAK2JAK1TYK2LCK | |
| SCHEMBL323219 | 0.79 | JAK3 (0.62) | JAK3JAK2JAK1TYK2LCK | |
| SCHEMBL322527 | 0.79 | JAK3 (0.73) | JAK3JAK2LCK | |
| SCHEMBL323325 | 0.79 | JAK3 (0.68) | JAK3JAK2LCK | |
| SCHEMBL323653 | 0.78 | JAK3 (0.67) | JAK3JAK2JAK1TYK2AKT1 | |
| SCHEMBL10320350 | 0.78 | JAK3 (0.55) | JAK3JAK2JAK1TYK2LCK | |
| SCHEMBL1047366 | 0.78 | JAK3 (0.55) | JAK3JAK2JAK1TYK2LCK | |
| SCHEMBL10231884 | 0.78 | JAK3 (0.69) | JAK3JAK2LCKAKT1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586961-B2 | Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2017-03-07 | — | — | US | claimed |
| EP-2590981-B1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2014-09-03 | — | — | EP | claimed |
| US-20130172325-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2013-07-04 | — | — | US | claimed |
| EP-2590981-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2013-05-15 | — | — | EP | claimed |
| WO-2012003829-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2012-01-12 | — | — | WO | claimed |
| US-9586961-B2 | Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2017-03-07 | — | — | US | disclosed |
| US-9586961-B2 | Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2017-03-07 | — | — | US | disclosed |
| EP-2590981-B1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2014-09-03 | — | — | EP | disclosed |
| US-20130172325-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2013-07-04 | — | — | US | disclosed |
| US-20130172325-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2013-07-04 | — | — | US | disclosed |
| US-20130172325-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2013-07-04 | — | — | US | disclosed |
| EP-2590981-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012003829-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172325-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | JAK1, JAK2, JAK3 | JAK3 3/4885JAK2 2/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.